despit
prophylact
therapi
common
bacteri
viral
opportunist
pathogen
periop
postop
period
infect
second
common
caus
death
cardiovascular
diseas
cvd
renal
transplant
recipi
accord
us
renal
data
system
usrd
infect
occur
rate
per
patientyear
first
year
transplant
common
infect
bacteri
follow
viral
fungal
parasit
infect
rare
notabl
cytomegaloviru
cmv
herp
simplex
viru
hsv
infect
rate
decreas
sinc
result
effect
antivir
prophylaxi
hepat
b
viru
hbv
hepat
c
viru
hcv
infect
rate
increas
period
unclear
reason
type
occurr
infect
immunocompromis
transplant
recipi
follow
timet
pattern
fig
although
rare
bloodborn
kidney
infect
transmit
donat
includ
viral
infect
eg
hcv
hbv
human
immunodefici
viru
hiv
cmv
bk
among
other
parasit
infect
malaria
babesia
bacteri
infect
undiagnos
bacteremia
renal
infect
infect
first
month
due
common
bacteria
candida
acquir
hospit
set
except
hsv
viral
infect
uncommon
period
similar
follow
major
surgic
procedur
bacteri
infect
period
involv
wound
cathet
drainag
site
aspir
pneumonia
urinari
tract
infect
uti
common
infect
specif
renal
transplant
recipi
includ
perinephr
fluid
collect
due
lymphocel
wound
hematoma
urin
leak
indwel
urinari
stent
uti
secondari
urinari
tract
abnorm
ureter
strictur
vesicoureter
reflux
neurogen
bladder
uti
caus
common
gramneg
bacteria
escherichia
coli
enterobacteriacea
pseudomona
gramposit
bacteria
enterococcu
prevent
measur
uti
includ
earli
urethr
cathet
remov
antibiot
prophylaxi
trimethoprimsulfamethoxazol
ciprofloxacin
prophylaxi
first
month
transplant
effect
reduc
frequenc
uti
less
essenti
elimin
urosepsi
unless
anatom
function
derang
urinari
tract
present
infect
multidrugresist
microorgan
recent
emerg
import
caus
morbid
mortal
organ
transplant
henc
center
routin
use
antibiot
prophylaxi
longer
recommend
although
strict
asept
surgic
techniqu
periop
use
firstgener
cephalosporin
reduc
incid
wound
infect
infect
still
observ
especi
subject
comorbid
condit
diabet
mellitu
dm
obes
antibioticassoci
clostridium
difficil
infect
particularli
cephalosporin
ciprofloxacin
amoxicillinclavulan
becom
seriou
epidemiolog
problem
worldwid
judici
use
antibiot
prophylact
therapi
may
decreas
incid
iatrogen
c
difficil
infect
wherea
infect
first
month
due
routin
bacteri
infect
nosocomi
outbreak
also
report
rarer
infect
legionella
contamin
hospit
water
suppli
month
opportunist
infect
secondari
immunosuppress
common
viral
infect
cmv
hsv
varicellazost
viru
vzv
epsteinbarr
viru
ebv
hbv
hcv
may
occur
exogen
infect
reactiv
latent
diseas
due
immunosuppress
state
repeat
cours
antibiot
corticosteroid
therapi
increas
risk
fungal
infect
wherea
viral
infect
may
result
immunosuppress
may
impair
immun
increas
risk
addit
opportunist
infect
opportunist
infect
may
occur
pneumocysti
jiroveci
previous
pneumocysti
carinii
aspergillu
speci
listeria
monocytogen
nocardia
speci
toxoplasma
gondii
trimethoprimsulfamethoxazol
prophylaxi
see
earli
posttransplant
period
outbreak
donortransmit
viral
infect
lymphocyt
choriomening
west
nile
viru
report
lymphocyt
choriomening
occur
within
first
week
transplant
associ
greater
mortal
rate
late
posttransplant
period
infect
communityacquir
viral
pathogen
includ
vaccineprevent
diseas
mump
measl
reemerg
current
effect
antivir
therapi
either
infect
adher
current
guidelin
vaccin
solid
organ
transplant
recommend
discuss
later
emerg
reemerg
viral
infect
includ
adenoviru
human
herpesviru
metapneumoviru
parainfluenza
respiratori
syncyti
viru
interestingli
rare
case
due
sever
acut
respiratori
syndrom
sar
coronaviru
report
follow
section
discuss
select
infect
renal
transplant
recipi
suggest
prophylact
therapi
shown
figur
cmv
infect
may
primari
infect
seroneg
recipi
donor
seroposit
recipi
seroneg
reactiv
endogen
latent
viru
donor
seroposit
seroneg
recipi
seroposit
superinfect
new
viru
strain
seroposit
recipi
donor
seroposit
recipi
seroposit
primari
cmv
infect
usual
sever
reactiv
infect
superinfect
cmv
infect
occur
primarili
first
month
transplant
continu
signific
caus
morbid
first
month
organ
transplant
direct
indirect
effect
cmv
infect
may
asymptomat
present
mononucleosislik
syndrom
influenzalik
ill
fever
leukopenia
thrombocytopenia
sever
system
diseas
hepat
esophag
gastroenter
colon
ulcer
pneumonia
chorioretin
associ
retin
hemorrhag
even
otiti
may
occur
enter
drain
pancrea
transplant
cmv
report
caus
bleed
ulcer
duoden
segment
clinic
manifest
usual
month
infect
risk
categor
basi
patient
statu
first
categori
consist
major
transplant
recipi
satisfactori
good
allograft
function
rel
low
dose
immunosuppress
medic
histori
chronic
viral
infect
risk
infect
patient
similar
gener
popul
communityacquir
respiratori
virus
constitut
major
infect
agent
opportunist
infect
unusu
unless
environment
exposur
occur
second
group
approxim
patient
consist
chronic
viral
infect
may
includ
hbv
hcv
cmv
ebv
bk
viru
papillomaviru
set
immunosuppress
viral
infect
may
lead
develop
progress
liver
diseas
cirrhosi
hbv
hcv
bk
nephropathi
posttransplant
lymphoprolif
diseas
ebv
squamou
cell
carcinoma
papillomaviru
third
group
approxim
patient
consist
experi
multipl
episod
reject
requir
repeat
exposur
heavi
immunosuppress
patient
like
develop
chronic
viral
infect
superinfect
opportunist
organ
caus
opportunist
pathogen
includ
p
jiroveci
l
monocytogen
nocardia
asteroid
cryptococcu
neoforman
geograph
restrict
mycos
coccidioidomycosi
histoplasmosi
blastomycosi
paracoccidioidomycosi
highrisk
candid
lifelong
prophylact
therapi
trimethoprimsulfamethoxazol
mg
mg
daili
advoc
lifelong
antifung
prophylaxi
also
consid
environment
exposur
minim
primarili
avoid
pigeon
area
activ
build
construct
sever
uncommon
viral
infect
recent
report
earli
late
posttransplant
period
figur
timet
infect
geograph
focus
infect
need
consid
certain
case
malaria
leishmaniasi
trypanosomiasi
strongyloidiasi
sourc
infect
specif
recipi
renal
transplant
perinephr
fluid
collect
eg
lymphocel
wound
hematoma
urin
leak
indwel
urinari
stent
anatom
function
genitourinari
tract
abnorm
eg
ureter
strictur
vesicoureter
reflux
neurogen
bladder
blood
cmv
dna
polymeras
chain
reaction
pcr
antigenemia
surveil
studi
former
assay
highli
specif
sensit
detect
cmv
viremia
latter
semiquantit
fluoresc
assay
circul
neutrophil
stain
nonspecif
uptak
cmv
earli
antigen
variou
prophylact
preemptiv
protocol
develop
oral
acyclovir
provid
effect
cmv
prophylaxi
sole
recipi
seroneg
donor
organ
oral
intraven
ganciclovir
oral
valganciclovir
provid
superior
prophylact
preemptiv
therapi
primari
cmv
infect
cmv
reactiv
prophylact
preemptiv
therapi
base
intens
immunosuppress
ie
antilymphocyt
antibodi
therapi
seroposit
statu
donor
recipi
seroneg
individu
receiv
organ
latent
infect
seroposit
donor
greatest
risk
primari
infect
sever
cmv
diseas
suggest
cmv
prophylaxi
protocol
shown
figur
clinic
cmv
diseas
treat
intraven
ganciclovir
mgkg
twice
daili
week
dose
adjust
renal
dysfunct
reduct
immunosuppress
withhold
mmf
treatment
continu
clearanc
viremia
assess
pcr
antigenemia
anecdot
report
suggest
calcineurin
inhibitor
cni
sirolimu
switch
conjunct
ganciclovir
therapi
may
benefici
patient
appar
ganciclovirresist
cmv
patient
gastrointestin
cmv
infect
use
assay
unreli
repeat
endoscopi
consid
assess
respons
therapi
patient
primari
infect
respond
slowli
therapi
addit
cmv
hyperimmun
globulin
mgkg
per
dose
given
intraven
everi
week
month
may
benefit
patient
tissu
invas
diseas
intraven
ganciclovir
recommend
convers
oral
therapi
evid
good
respons
follow
cours
oral
ganciclovir
valganciclovir
prophylaxi
wherea
oral
valganciclovir
provid
good
bioavail
may
effect
mild
cmv
diseas
recommend
treatment
occur
month
transplant
except
chorioretin
occur
later
transplant
cours
quantit
cmv
assay
serum
patient
invas
coliti
gastriti
neurolog
diseas
includ
chorioretin
often
neg
diagnosi
case
may
requir
invas
test
biopsi
cmv
infect
associ
immun
modul
dysregul
helpersuppressor
cell
may
risk
factor
chronic
allograft
reject
secondari
infect
opportunist
agent
p
jiroveci
candida
aspergillu
reactiv
human
herpesviru
develop
posttransplant
lymphoprolif
diseas
cmv
infect
also
associ
acceler
hcv
infect
develop
newonset
dm
transplant
donor
recipi
seroposit
statu
use
blood
product
cmvseroposit
donor
wellestablish
risk
factor
cmv
infect
factor
associ
increas
risk
cmv
infect
includ
use
antilymphocyt
antibodi
prolong
repeat
cours
antilymphocyt
prepar
comorbid
ill
neutropenia
acut
reject
episod
mycophenol
mofetil
mmf
report
increas
risk
cmv
viremia
cmv
diseas
studi
especi
patient
receiv
gday
although
causeeffect
allograft
reject
cmv
infect
remain
conjectur
sever
studi
suggest
one
may
increas
risk
possibl
owe
releas
inflammatori
cytokin
prevent
cmv
infect
exampl
result
lower
incid
graft
reject
prophylact
therapi
begin
immedi
postop
period
preemptiv
therapi
involv
treatment
found
seroconvert
quantit
laboratori
assay
check
dehydrogenas
defici
initi
therapi
order
efficaci
fluconazol
recommend
recipi
combin
kidneypancrea
combin
kidneyliv
transplant
consid
reinstitut
prophylact
therapi
month
acut
reject
episod
requir
intensif
immunosuppress
cmv
cytomegaloviru
trimethoprimsulfamethoxazol
tmpit
routin
use
reduc
elimin
incid
smz
mg
one
tablet
daili
pneumocysti
jiroveci
listeria
monocytogen
month
nocardia
asteroid
toxoplasma
gondii
renal
transplant
recipi
tmpsmz
reduc
incid
urinari
tract
infect
monthli
intraven
aerosol
replac
tmpsmz
patient
sulfa
allergi
pentamidin
dapson
atovaquon
nystatin
unitsml
ml
fungal
prophylaxi
meal
bedtim
fluconazol
mg
one
tablet
daili
close
monitor
cyclosporin
tacrolimu
level
month
start
stop
antifung
agent
acyclovirvalganciclovirganciclovir
cmv
prophylaxi
see
figur
bk
viru
ubiquit
human
viru
peak
incid
primari
infect
children
year
age
seropreval
rate
among
adult
popul
worldwid
primari
infect
bk
viru
preferenti
establish
latenc
within
genitourinari
tract
frequent
reactiv
set
immunosuppress
renal
transplant
recipi
bk
viru
associ
rang
clinic
syndrom
includ
asymptomat
viruria
without
viremia
ureter
stenosi
obstruct
interstiti
nephriti
bk
allograft
nephropathi
last
decad
bk
nephropathi
emerg
import
caus
allograft
dysfunct
renal
transplant
seri
report
renal
transplant
recipi
develop
bk
viruria
develop
bk
viremia
develop
bk
nephropathi
highest
preval
bk
viruria
viremia
occur
month
month
respect
risk
develop
bk
viremia
increas
urin
viral
load
greater
copiesml
wherea
bk
nephropathi
unusu
absenc
bk
viremia
bk
nephropathi
commonli
present
asymptomat
rise
serum
creatinin
first
posttransplant
year
howev
bk
nephropathi
may
occur
earli
first
week
late
year
transplant
diagnosi
made
allograft
biopsi
demonstr
bk
viral
inclus
renal
tubular
cell
nuclei
occasion
glomerular
pariet
epithelium
fig
variabl
degre
interstiti
mononuclear
inflamm
fig
often
plasma
cell
degen
chang
tubul
focal
tubul
may
mimic
acut
reject
bk
nephropathi
often
associ
focal
sharpli
demarc
area
tubulointerstiti
inflamm
correspond
foci
viral
infect
immunohistochemistri
fig
situ
hybrid
electron
microscopi
requir
confirm
diagnosi
bk
infect
acut
reject
may
occur
simultan
distinguish
bk
nephropathi
acut
reject
presenc
diagnost
challeng
late
bk
nephropathi
characterist
intranuclear
inclus
seen
histolog
chang
may
indistinguish
chronic
reject
histolog
classif
system
bk
nephropathi
base
degre
activ
inflamm
acut
tubular
injuri
tubulointerstiti
scar
may
prognost
signific
urin
cytolog
decoy
cell
quantit
determin
viruria
viral
load
blood
propos
surrog
marker
diagnosi
bk
nephropathi
treatment
strategi
includ
reduct
immunosuppress
involv
reduct
discontinu
mmf
azathioprin
judici
reduct
cni
therapi
immunosuppress
regimen
switch
tacrolimu
cyclosporin
sirolimu
rapamycin
result
resolut
bk
nephropathi
viremia
viruria
anecdot
case
report
switch
cni
sirolimu
may
ad
benefit
avoid
longterm
nephrotox
effect
cni
therapi
although
approv
antivir
drug
avail
adjunct
therapi
leflunomid
cidofovir
quinolon
intraven
immun
globulin
ivig
may
benefici
especi
patient
progress
allograft
dysfunct
quinolon
prefer
center
low
cost
eas
administr
leflunomid
use
other
potenti
simultan
antivir
immunosuppress
properti
cidofovir
highli
concentr
urin
renal
tissu
use
lowdos
cidofovir
bk
nephropathi
report
devoid
nephrotox
seriou
advers
event
anecdot
establish
cmv
diseas
intraven
ganciclovir
requir
cidofovir
foscarnet
altern
therapeut
agent
view
nephrotox
potenti
synergist
nephrotox
cni
reserv
use
ganciclovirresist
strain
clinic
suspect
candida
infect
common
transplant
recipi
candida
albican
candida
tropicali
account
infect
dm
highdos
corticosteroid
broadspectrum
antibacteri
therapi
predispos
patient
mucocutan
candid
infect
oral
candidiasi
intertrigin
candid
infect
esophag
vagin
uti
skin
infect
treat
nystatin
topic
clotrimazol
candid
uti
treat
fluconazol
voriconazol
rare
liposom
amphotericin
caspofungin
fluconazoleresist
speci
see
chapter
whenev
possibl
foreign
object
bladder
cathet
surgic
drain
eg
percutan
nephrostomi
tube
urinari
stent
promptli
remov
ideal
manag
asymptomat
candiduria
immunocompromis
patient
remain
uncertain
see
chapter
short
cours
day
fluconazol
gener
recommend
system
antifung
therapi
indic
presenc
posit
blood
cultur
candida
speci
cmv
statu
unknown
give
intraven
dhpg
cmv
statu
determin
dose
adjust
renal
function
necessari
dhpg
guanin
although
lowdos
valganciclovir
mg
daili
shown
effect
canadian
societi
transplant
consensu
workshop
cmv
manag
recommend
dose
valganciclovir
mg
daili
cmv
recipi
cmv
organ
kidney
liver
pancrea
heart
refer
prophylaxi
protocol
acyclovir
mg
daili
valganciclovir
mg
daili
month
cmv
dna
everi
week
month
antibodi
treatment
dhpg
mgkg
iv
everyday
follow
antibodi
treatmentvalganciclovir
mg
po
everyday
month
antibodi
treatment
valganciclovir
mg
everyday
month
cmv
dna
everi
week
x
month
antibodi
treatment
dhpg
mgkg
iv
everyday
follow
antibodi
treatment
valganciclovir
mg
po
everyday
month
antibodi
treatment
acyclovir
mg
daili
valganciclovir
mg
daili
month
cmv
dna
everi
week
month
antibodi
treatment
dhpg
mgkg
iv
everyday
follow
antibodi
treatment
valganciclovir
mg
po
everyday
month
antibodi
treatment
acyclovir
mg
daili
valganciclovir
mg
daili
month
cmv
dna
everi
week
month
report
suggest
ivig
may
effect
treat
corticosteroidresist
reject
use
may
benefici
patient
concomit
reject
bk
nephropathi
histopatholog
chang
indistinguish
reject
despit
treatment
patient
establish
bk
nephropathi
develop
progress
declin
renal
function
graft
loss
earli
diagnosi
intervent
may
improv
prognosi
intens
monitor
urin
serum
bk
pcr
first
year
preemptiv
reduct
immunosuppress
therapi
may
lead
resolut
viremia
prevent
bk
nephropathi
absenc
activ
viral
replic
patient
graft
loss
due
bk
nephropathi
safe
undergo
retransplant
activ
surveil
bk
viru
reactiv
transplant
recommend
suggest
guidelin
posttransplant
screen
monitor
bk
replic
shown
figur
tuberculosi
tb
infect
renal
transplant
recipi
vari
accord
preval
gener
popul
eg
incid
tb
transplant
recipi
report
occur
unit
state
compar
south
africa
india
pakistan
tb
infect
transplant
recipi
result
reactiv
dormant
lesion
set
immunosuppress
therapi
henc
renal
transplant
candid
ppd
skin
test
tuberculin
skin
test
place
transplant
posit
skin
test
respons
prior
histori
tb
mandat
evalu
rule
activ
diseas
isoniazid
prophylaxi
total
month
recommend
posit
skin
test
respons
interest
patient
develop
tb
transplant
neg
ppd
skin
test
result
transplant
center
recommend
isoniazid
prophylact
therapi
select
ppdneg
patient
histori
inadequ
treat
tb
radiograph
evid
granulomat
diseas
histori
adequ
treatment
organ
ppdposit
donor
close
prolong
contact
case
activ
tb
patient
known
histori
adequ
treat
tb
infect
advoc
use
isoniazid
prophylaxi
first
month
transplant
intensif
immunosuppress
other
howev
suggest
isoniazid
prophylaxi
indic
patient
whose
tb
properli
treat
clinic
radiolog
cultur
evid
activ
tb
infect
contraind
transplant
enzymelink
immunospot
elispot
detect
cell
specif
mycobacterium
tuberculosi
antigen
unaffect
bacil
bcg
vaccin
becom
major
advanc
tb
screen
center
tuberculin
skin
test
replac
elispot
assay
tspottb
assay
rare
import
caus
infect
transplant
patient
particularli
endem
area
southeast
asia
strongyloid
presenc
immunosuppress
hyperinfect
syndrom
may
observ
parasit
pneumonia
fig
gastrointestin
involv
posttransplant
gastrointestin
complic
common
aris
varieti
caus
select
complic
discuss
comprehens
review
nystatin
swish
swallow
first
month
transplant
recommend
highrisk
candid
includ
liver
pancrea
transplant
recipi
receiv
antilymphocyt
antibodi
therapi
fluconazol
prophylact
therapi
month
warrant
clostridium
difficil
infect
may
asymptomat
present
diarrhea
intestin
obstruct
even
fulmin
pseudomembran
coliti
toxic
megacolon
perfor
c
difficil
coliti
report
transplant
recipi
risk
factor
includ
young
year
advanc
age
femal
gender
use
monoclon
antibodi
treat
acut
reject
episod
intraabdomin
graft
placement
among
transplant
recipi
receiv
antimicrobi
therapi
c
difficileassoci
diarrhea
develop
approxim
patient
mild
case
c
difficil
infect
oral
metronidazol
effect
oral
vancomycin
prefer
firstlin
treatment
treatment
failur
howev
requir
treatment
oral
vancomycin
sever
ill
patient
gastrointestin
dysmotil
ileu
oral
agent
may
reach
colon
mucosa
metronidazol
administ
intraven
sever
colon
diseas
refractori
medic
treatment
may
necessit
colectomi
helicobact
pylori
infect
associ
wide
rang
gastrointestin
complic
includ
chronic
gastriti
duoden
gastric
ulcer
mucosaassoci
lymphoid
tissu
malt
lymphoma
gastric
carcinoma
gener
popul
recipi
solid
organ
transplant
treatment
includ
tripledrug
regimen
consist
two
antibiot
acidsuppress
agent
h
blocker
proton
pump
inhibitor
firstlin
h
pylori
regimen
recommend
american
colleg
gastroenterolog
shown
figur
recipi
orthotop
heart
transplant
tripledrug
therapi
result
lower
erad
rate
compar
gener
popul
suggest
immunosuppress
may
hinder
clearanc
h
pylori
unexplain
dyspept
reflux
symptom
investig
endoscopi
biopsi
exclud
malign
transform
h
pylori
recogn
risk
factor
malt
lymphoma
may
occur
kidney
liver
heart
transplant
recipi
renal
transplant
recipi
infect
h
pylori
malt
lymphoma
may
less
aggress
lymphoma
disord
may
cure
erad
h
pylori
posttransplant
colon
complic
diverticul
colon
perfor
may
lifethreaten
difficult
diagnos
symptom
may
mask
immunosuppress
therapi
particularli
earli
postop
period
diverticul
complic
perfor
abscess
format
phlegmon
fistula
report
occur
renal
transplant
recipi
may
increas
patient
polycyst
kidney
diseas
pkd
earli
posttransplant
colon
perfor
larg
due
highdos
corticosteroid
diverticul
cmv
coliti
intestin
ischemia
perfor
occur
late
year
transplant
commonli
due
diverticulosi
malign
diseas
abdomin
symptom
may
absent
effect
immunosuppress
may
suggest
posttransplant
gastrointestin
complic
reader
refer
chapter
refer
mmf
commonli
caus
gastrointestin
side
effect
includ
nausea
vomit
dyspepsia
anorexia
flatul
diarrhea
dose
reduct
transient
discontinu
drug
divid
dose
three
four
time
day
often
amelior
resolv
symptom
switch
entericco
formul
mmf
may
improv
gastrointestin
toler
patient
consist
shown
better
origin
formul
larg
random
doubleblind
studi
use
patientreport
outcom
assess
impact
gastrointestin
symptom
patient
healthrel
qualiti
life
symptom
burden
current
way
sirolimu
may
caus
oral
mucocutan
lesion
confus
hsv
cmv
infect
cultur
neg
drugrel
oral
ulcer
usual
resolv
discontinu
offend
agent
sirolimu
tacrolimu
cyclosporin
also
suggest
caus
diarrhea
patient
posttransplant
infect
gastrointestin
tract
may
viral
fungal
bacteri
etiolog
viral
infect
commonli
caus
cmv
hsv
c
albican
c
tropicali
common
opportunist
fungal
infect
leukoplakia
posttransplant
lymphoprolif
disord
ptld
may
develop
patient
ebv
infect
ptld
discuss
later
section
commonli
encount
bacteri
pathogen
includ
clostridium
difficil
helicobact
pylori
cmv
affect
segment
gastrointestin
tract
patient
may
present
dysphagia
odynophagia
nausea
vomit
gastroparesi
abdomin
pain
diarrhea
gastrointestin
bleed
leukopenia
elev
transaminas
common
persist
unexplain
symptom
nausea
vomit
diarrhea
particularli
earli
posttransplant
period
intensif
immunosuppress
warrant
investig
upper
lower
endoscopi
biopsi
hsv
infect
result
primarili
reactiv
endogen
latent
viru
caus
clinic
infect
within
first
month
transplant
patient
commonli
present
oral
mucocutan
lesion
gingivostomat
without
odynophagia
dysphagia
hsv
esophag
note
occur
patient
receiv
highdos
corticosteroid
antilymphocyt
prepar
acut
reject
limit
oral
mucocutan
lesion
treat
oral
acyclovir
extens
infect
requir
intraven
acyclovir
ganciclovir
rare
case
hsv
hepat
report
routin
use
acyclovir
prophylaxi
earli
posttransplant
period
recommend
candida
stomat
esophag
common
first
month
transplant
increas
subject
leukopenia
sever
immunosuppress
diabet
concomit
infect
bleed
perfor
format
tracheoesophag
fistula
report
prophylact
oral
recipi
organ
transplant
increas
risk
develop
neoplasm
compar
gener
popul
similar
posttransplant
infecti
complic
time
occurr
differ
type
malign
neoplasm
transplant
appear
follow
timet
pattern
israel
penn
intern
transplant
tumor
registri
data
time
appear
differ
neoplasm
solid
organ
transplant
shown
figur
ptld
gener
occur
earli
transplant
skin
cancer
occur
increas
frequenc
time
intens
durat
immunosuppress
well
abil
agent
promot
replic
variou
oncogen
virus
import
risk
factor
associ
human
papillomavirus
cervic
vulvar
carcinoma
ebv
ptld
hbv
hcv
hepatocellular
carcinoma
kaposi
sarcoma
well
establish
figur
provid
summari
presenc
tachypnea
tachycardia
mortal
colon
perfor
high
manag
includ
prompt
exterior
perfor
colon
earli
broadspectrum
antimicrobi
therapi
minim
immunosuppress
therapi
although
uncommon
presenc
abdomin
pain
gastrointestin
bleed
unexplain
fever
weight
loss
rais
suspicion
gastrointestin
tb
characterist
endoscop
find
includ
circular
ulcer
small
diverticula
sessil
polyp
presenc
caseat
granuloma
acidfast
bacilli
confirm
diagnosi
potenti
renal
transplant
candid
receiv
immun
hepat
b
pneumococcu
standard
immun
appropri
age
uptod
recommend
routin
adult
immun
avail
center
diseas
control
prevent
websit
wwwcdcgovniprec
adultschedulepdf
immun
ideal
administ
least
week
transplant
achiev
optim
immun
respons
minim
possibl
live
vaccinederiv
infect
posttransplant
period
household
member
close
contact
health
care
worker
also
fulli
immun
live
viru
live
organ
vaccin
avoid
transplant
includ
measlesmumpsrubella
mmr
live
oral
polioviru
also
contraind
household
contact
smallpox
vaccinia
varicella
yellow
fever
adenoviru
live
oral
typhoid
bcg
intranas
influenza
vaccin
addit
exposur
person
chickenpox
herp
zoster
avoid
lesion
crust
new
lesion
appear
vaccin
use
inactiv
kill
microorgan
compon
recombin
moieti
safe
transplant
recipi
includ
hepat
hepat
b
intramuscular
influenza
b
pneumococc
haemophilu
influenza
b
inactiv
polio
viru
vaccin
diphtheriapertussistetanu
dpt
neisseria
meningitidi
gener
vaccin
avoid
first
month
transplant
potenti
stimul
immun
respons
higher
chanc
graft
dysfunct
reject
addit
vaccin
within
first
month
transplant
often
ineffect
heavi
immunosuppress
prevent
infect
adult
travel
solid
organ
transplant
reader
refer
refer
recommend
vaccin
transplant
list
figur
standarddos
ppi
twice
daili
esomeprazol
daili
clarithromycin
mg
twice
daili
amoxicillin
mg
twice
daili
day
ye
standarddos
ppi
twice
daili
clarithromycin
mg
twice
daili
metronidazol
mg
twice
daili
day
ye
bismuth
subsalicyl
mg
oral
time
daili
metronidazol
mg
oral
time
daili
tetracyclin
mg
oral
four
time
daili
ranitidin
mg
oral
twice
daili
standarddos
ppi
daili
twice
daili
day
measlesmumpsrubella
x
renal
cell
carcinoma
breast
carcinoma
analysi
registri
data
involv
patient
histori
pretransplant
prostat
adenocarcinoma
renal
heart
liver
transplant
recipi
prostat
cancer
recurr
found
relat
stage
diseas
initi
diagnosi
tumor
recurr
rate
stage
stage
ii
stage
iii
diseas
respect
henc
longer
wait
time
may
necessari
advanc
diseas
suggest
guidelin
tumorfre
wait
period
common
pretransplant
malign
neoplasm
shown
figur
ptld
common
posttransplant
malign
neoplasm
children
adult
second
common
malign
neoplasm
skin
cancer
ptld
report
occur
renal
transplant
recipi
major
ptld
nonhodgkin
lymphoma
bcell
origin
link
ebv
infect
base
world
health
organ
classif
ptld
divid
three
distinct
morpholog
group
diffus
bcell
hyperplasia
polymorph
ptld
usual
monoclon
monomorph
ptld
includ
highgrad
invas
lymphoma
bor
tlymphocyt
centroblast
diffus
bcell
hyperplasia
usual
seen
children
young
adult
commonli
occur
within
first
year
transplant
polymorph
ptld
repres
common
type
ptld
children
adult
may
occur
time
transplant
contrast
monomorph
bcell
ptld
often
seen
sever
year
transplant
may
resembl
nonhodgkin
lymphoma
gener
popul
retrospect
analysi
registri
data
recipi
kidney
transplant
ptld
occur
median
month
rang
month
transplant
ptld
may
present
constitut
symptom
fever
night
sweat
weight
loss
local
symptom
respiratori
tract
infect
mass
includ
tonsillar
even
gingiv
involv
gastrointestin
tract
diarrhea
pain
perfor
bleed
mass
central
nervou
system
cn
headach
seizur
confus
contrast
lymphoma
gener
popul
lymph
node
almost
alway
involv
lymph
node
involv
absent
patient
ptld
risk
factor
ptld
includ
primari
ebv
infect
younger
age
anteced
histori
cmv
diseas
use
antilymphocyt
antibodi
eg
antithymocyt
globulin
histori
pretransplant
malign
diseas
fewer
hla
match
associ
increas
risk
ptld
cyclosporin
tacrolimu
may
enhanc
develop
ebvassoci
ptld
directli
promot
surviv
ebvinfect
b
cell
presum
inhibit
ebvtransform
cell
apoptosi
reduct
discontinu
immunosuppress
therapi
particularli
antilymphocyt
antibodi
cyclosporin
tacrolimu
mmf
recommend
firstlin
treatment
prednison
increas
mg
daili
prevent
allograft
reject
sirolimu
strong
antiprolif
effect
ptldderiv
bcell
line
whether
sirolimu
may
limit
bcell
lymphoma
growth
simultan
provid
immunosuppress
prevent
graft
reject
await
studi
acyclovir
ganciclovir
therapi
reduct
immunosuppress
benefici
may
cur
benign
polyclon
bcell
prolifer
incid
cancer
relat
infect
transplant
recipi
analysi
usrd
databas
document
cancer
rate
common
cancer
colon
lung
prostat
stomach
esophagu
pancrea
ovari
breast
nearli
twofold
higher
kidney
transplant
compar
gener
popul
although
registri
studi
limit
transplant
recipi
adher
standard
cancer
surveil
appropri
age
fig
patient
histori
pretransplant
malign
neoplasm
close
monitor
recurr
posttransplant
period
mandatori
highest
recurr
rate
observ
multipl
myeloma
nonmelanoma
skin
cancer
bladder
carcinoma
sarcoma
symptomat
mgm
patient
ptld
conjunct
reduct
immunosuppress
shown
promis
result
complet
remiss
rate
report
although
respons
rate
appear
vari
substanti
among
patient
center
rituximab
conjunct
reduct
immunosuppress
evolv
treatment
choic
ptld
role
cytokinebas
therapi
interferon
alfa
remain
poorli
defin
increas
risk
allograft
reject
seen
treatment
sirolimu
immunosuppress
antiprolif
properti
demonstr
prevent
prolifer
bcell
tcell
ptldderiv
tumor
cell
line
vitro
vivo
limit
data
nine
european
transplant
center
shown
tumor
regress
patient
ptld
underw
minim
withdraw
cni
sirolimu
convers
factor
advers
affect
surviv
includ
multipleversu
singlesit
involv
increas
age
bcell
predomin
use
antilymphocyt
globulin
antithymocyt
globulin
earli
versu
late
onset
within
month
versu
month
recipi
renal
transplant
ptld
restrict
allograft
alon
transplant
nephrectomi
may
improv
surviv
role
antivir
therapi
bcell
monoclon
malign
transform
less
well
defin
mortal
report
despit
antivir
therapi
surgic
resect
without
adjunct
local
irradi
suggest
local
diseas
local
irradi
advoc
treatment
choic
ptld
involv
central
nervou
system
lesion
amen
surgeri
aggress
monoclon
type
ptld
chemotherapi
use
favor
result
compar
reduct
immunosuppress
alon
frequent
use
regimen
chop
cyclophosphamid
doxorubicin
adriamycin
vincristin
prednison
vapecb
doxorubicin
etoposid
cyclophosphamid
methotrex
bleomycin
vincristin
report
promis
novel
therapi
includ
promacecytabom
prednison
oral
doxorubicin
cyclophosphamid
etoposidecytarabin
bleomycin
vincristin
oncovin
methotrex
advers
effect
chemotherapi
includ
high
mortal
rate
sepsi
treatmentrel
toxic
rituximab
chimer
monoclon
antibodi
murin
variabl
region
target
antigen
human
constant
region
antitumor
activ
bcell
lymphoma
earli
experi
rituximab
two
six
weekli
dose
figur
prevent
care
recommend
cancer
surveil
renal
transplant
recipi
recommend
american
transplant
societi
european
best
practic
guidelin
renal
transplant
american
colleg
prevent
medicin
recommend
regular
screen
highrisk
individu
none
lowrisk
individu
neoplasm
propos
expert
field
immunosuppress
dose
reduct
withdraw
may
permit
recoveri
immun
system
control
progress
lifethreaten
malign
neoplasm
former
allow
intact
immun
surveil
malign
cell
nonetheless
approach
without
attend
risk
graft
reject
graft
loss
furthermor
littl
known
much
extent
immunosuppress
reduct
withdraw
might
alter
natur
histori
establish
posttransplant
malign
neoplasm
opinion
cni
sirolimu
switch
cni
minim
conjunct
sirolimu
may
viabl
therapeut
option
antitumor
effect
sirolimu
discuss
later
patient
metastat
cancer
manipul
immunosuppress
probabl
futil
risk
reject
graft
loss
necessit
return
dialysi
like
outweigh
benefit
studi
suggest
immunosuppress
agent
differ
effect
cancer
risk
transplant
carcinogen
effect
antithymocyt
globulin
cyclosporin
tacrolimu
azathioprin
well
document
contrast
azathioprin
mmf
shown
antiprolif
effect
suggest
protect
posttransplant
malign
neoplasm
analysi
adult
patient
preexist
dm
indic
significantli
higher
incid
malign
transform
azathioprinetr
mmftreat
patient
versu
p
howev
whether
mmf
protect
posttransplant
malign
neoplasia
remain
specul
preclin
clinic
studi
demonstr
mtor
inhibitor
sirolimu
everolimu
antiprolif
antitumor
effect
earli
studi
renal
transplant
recipi
demonstr
lower
incid
skin
cancer
sirolimusbas
therapi
without
cyclosporin
sirolimu
mainten
therapi
earli
cyclosporin
withdraw
compar
remain
cyclosporin
sirolimu
combin
therapi
suggest
protect
effect
sirolimu
skin
cancer
due
inhibit
sever
ultraviolet
lightinduc
mechan
involv
skin
carcinogenesi
malign
data
rapamun
mainten
regimen
trial
demonstr
lower
incid
skin
nonskin
cancer
year
transplant
recipi
receiv
sirolimusbas
therapi
cyclosporin
withdraw
month
compar
receiv
sirolimu
cyclosporin
combin
therapi
sirolimu
therapi
also
report
result
success
clinic
histolog
remiss
kaposi
sarcoma
renal
transplant
recipi
although
sirolimu
appear
provid
satisfactori
outcom
certain
cancer
transplant
use
manag
malign
diseas
solid
organ
transplant
remain
defin
tailor
individu
patient
consensu
manag
immunosuppress
therapi
patient
posttransplant
malign
